The mission is to save and ameliorate lives around the world through the discovery, development and production of innovative products and services within the realm of biotechnology.
INDUS Gene differentiates itself by the unique vision developed by its founder, Dr.C. Channa Reddy, distinguished Professor at Pennsylvania State University. The broad and ambitious scope of the vision not only includes the construction of the world's premier cGMP contract manufacturing operation, but also the inclusion of the establishment of a facility that is entirely green, which is based on solar power, and that will be known to have an international reputation of excellence regarding the biopharmaceutical industry. Indus Gene considers one of its primary goals to become a leader in the production of human and animal health products.
A continuing trend seems to be that biotechnology is the quickest growing sub sector within the pharmaceutical industry. Indus Gene will participate in the rapidly growing worldwide contract manufacturing of biopharmaceuticals, which is expected to grow from nearly $90 billion today to approximately $120 billion by 2016 in US alone. Currently US pharmaceutical companies outsource close to 30% of their biopharmaceutical manufacturing and it is expected to reach 60% by 2016.
Therefore, Indus Gene’s marketing opportunities for contract manufacturing of biopharmaceuticals include the largest pharmaceutical companies like Pfizer, GlaxoSmithKline, Novartis, Johnson and Johnson, etc. in the US. Indus Gene expects our South India plant to contribute significantly to the overall biopharmaceutical business and allow it to expand eventually its customer base around the world.